Oral Ozanimod Efficacy and Safety Results at 2 Years from Phase 2 RADIA
Ozanimod demonstrated continued efficacy over 96 weeks on MRI and clinical m...
2016-09-20
文传商讯
New analysis showed dose adjustment of Giotrif (afatinib) improved tole
A new analysis from two Phase III trials published in Annals of Oncology sho...
2016-09-09
文传商讯
Oral Ozanimod 72-Week Phase 2 Results From RADIANCE Trial in Relapsing
Reductions in brain lesions at week 24 were maintained while relapses were f...
2016-02-21
文传商讯
